ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the U.S. launch of the next-generation LifeVest wearable cardioverter defibrillator (WCD). This marks the fifth FDA-approved LifeVest WCD, which works with the recently launched next generation LifeVest WCD garment.
LifeVest delivers therapy for patients at risk of sudden cardiac death. The LifeVest WCD monitor incorporates response buttons directly into the monitor, which allows a conscious patient to delay an unnecessary treatment.
The last two generations of the LifeVest WCD monitor feature a large touchscreen, allowing patients to more easily interact with important messages from the system. The company said LifeVest is the only WCD that does not require an additional device for patients to interact directly with the system.
